These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27206801)

  • 1. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
    Irwin DE; Masaquel A; Johnston S; Barnett B
    J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
    Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
    J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
    Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
    Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
    Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
    J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
    Borker R
    J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
    Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
    J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.
    Simpson KN; Chen SY; Wu AW; Boulanger L; Chambers R; Nedrow K; Tawadrous M; Pashos CL; Haider S
    HIV Med; 2014 Sep; 15(8):488-98. PubMed ID: 24641448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder.
    Schein J; Cloutier M; Bungay R; Gauthier-Loiselle M; Childress A
    J Med Econ; 2024; 27(1):653-662. PubMed ID: 38602691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
    Shah A; Shah R; Kebede N; Mohamed A; Botteman M; Waldeck R; Hussain A
    J Med Econ; 2020 Apr; 23(4):330-346. PubMed ID: 31835965
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States.
    Korsnes JS; Goodwin BB; Murray M; Candrilli SD
    Ann Pharmacother; 2016 Dec; 50(12):989-1000. PubMed ID: 27439947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
    Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
    Hassett MJ; O'Malley AJ; Pakes JR; Newhouse JP; Earle CC
    J Natl Cancer Inst; 2006 Aug; 98(16):1108-17. PubMed ID: 16912263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs associated with adverse events for systemic therapies in metastatic melanoma.
    Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
    J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
    Hagiwara M; Borker R; Oster G
    Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.